CA3242987A1 - NEW VALPROIC ACID ANALOGUES AND MEDICAL TREATMENT METHODS USING THESE - Google Patents
NEW VALPROIC ACID ANALOGUES AND MEDICAL TREATMENT METHODS USING THESEInfo
- Publication number
- CA3242987A1 CA3242987A1 CA3242987A CA3242987A CA3242987A1 CA 3242987 A1 CA3242987 A1 CA 3242987A1 CA 3242987 A CA3242987 A CA 3242987A CA 3242987 A CA3242987 A CA 3242987A CA 3242987 A1 CA3242987 A1 CA 3242987A1
- Authority
- CA
- Canada
- Prior art keywords
- methods
- same
- medical treatment
- valproic acid
- novel analogs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/126—Acids containing more than four carbon atoms
- C07C53/128—Acids containing more than four carbon atoms the carboxylic group being bound to a carbon atom bound to at least two other carbon atoms, e.g. neo-acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
- C07C51/377—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by splitting-off hydrogen or functional groups; by hydrogenolysis of functional groups
- C07C51/38—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by splitting-off hydrogen or functional groups; by hydrogenolysis of functional groups by decarboxylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2118559.0 | 2021-12-20 | ||
| GB2118559.0A GB2613900B (en) | 2021-12-20 | 2021-12-20 | Novel compounds and methods of use thereof |
| PCT/GB2022/053318 WO2023118846A1 (en) | 2021-12-20 | 2022-12-20 | Novel analogs of valproic acid and methods of medical treatment using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3242987A1 true CA3242987A1 (en) | 2023-06-29 |
Family
ID=84887257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3242987A Pending CA3242987A1 (en) | 2021-12-20 | 2022-12-20 | NEW VALPROIC ACID ANALOGUES AND MEDICAL TREATMENT METHODS USING THESE |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250066282A1 (https=) |
| EP (1) | EP4452917A1 (https=) |
| JP (1) | JP2025500459A (https=) |
| KR (1) | KR20240152301A (https=) |
| CN (1) | CN118613464A (https=) |
| AU (1) | AU2022422574A1 (https=) |
| CA (1) | CA3242987A1 (https=) |
| GB (1) | GB2613900B (https=) |
| IL (1) | IL313669A (https=) |
| MX (1) | MX2024007654A (https=) |
| WO (1) | WO2023118846A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2644641A (en) * | 2024-09-24 | 2026-04-29 | Cereno Scient Ab | New methods |
| WO2026068561A1 (en) | 2024-09-24 | 2026-04-02 | Cereno Scientific Ab | Valproic acid for use in treating pulmonary arterial hypertension |
| GB2644610A (en) * | 2024-09-27 | 2026-04-22 | Cereno Scient Ab | New methods |
| WO2026068552A1 (en) | 2024-09-24 | 2026-04-02 | Cereno Scientific Ab | Deuterated valproic acid compounds for use in treating pulmonary arterial hypertension |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120071554A1 (en) * | 2008-10-28 | 2012-03-22 | Liu Julie F | Deuterated 2-propylpentanoic acid compounds |
| US20100143507A1 (en) * | 2008-12-09 | 2010-06-10 | Auspex Pharmaceuticals, Inc. | Carboxylic acid inhibitors of histone deacetylase, gaba transaminase and sodium channel |
| GB201417828D0 (en) * | 2014-10-08 | 2014-11-19 | Cereno Scient Ab | New methods and compositions |
| RU2760304C2 (ru) * | 2016-04-08 | 2021-11-23 | Серено Сайентифик Аб | Фармацевтические составы с отсроченным высвобождением, содержащие вальпроевую кислоту, и их применение |
-
2021
- 2021-12-20 GB GB2118559.0A patent/GB2613900B/en active Active
-
2022
- 2022-12-20 MX MX2024007654A patent/MX2024007654A/es unknown
- 2022-12-20 CA CA3242987A patent/CA3242987A1/en active Pending
- 2022-12-20 JP JP2024538134A patent/JP2025500459A/ja active Pending
- 2022-12-20 AU AU2022422574A patent/AU2022422574A1/en active Pending
- 2022-12-20 IL IL313669A patent/IL313669A/en unknown
- 2022-12-20 WO PCT/GB2022/053318 patent/WO2023118846A1/en not_active Ceased
- 2022-12-20 EP EP22839416.9A patent/EP4452917A1/en active Pending
- 2022-12-20 CN CN202280084449.3A patent/CN118613464A/zh active Pending
- 2022-12-20 US US18/721,594 patent/US20250066282A1/en active Pending
- 2022-12-20 KR KR1020247024372A patent/KR20240152301A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GB2613900A (en) | 2023-06-21 |
| CN118613464A (zh) | 2024-09-06 |
| IL313669A (en) | 2024-08-01 |
| KR20240152301A (ko) | 2024-10-21 |
| MX2024007654A (es) | 2024-07-04 |
| GB2613900B (en) | 2024-01-17 |
| AU2022422574A1 (en) | 2024-07-18 |
| EP4452917A1 (en) | 2024-10-30 |
| US20250066282A1 (en) | 2025-02-27 |
| WO2023118846A1 (en) | 2023-06-29 |
| JP2025500459A (ja) | 2025-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3242987A1 (en) | NEW VALPROIC ACID ANALOGUES AND MEDICAL TREATMENT METHODS USING THESE | |
| JP2971053B2 (ja) | ヒドロキサム酸誘導体の合成中間体 | |
| JPH10504821A (ja) | 金属タンパク質分解酵素阻害剤 | |
| US6423690B1 (en) | Antibacterial agents | |
| EP0489579B1 (en) | Peptidyl derivatives | |
| DE69516143T2 (de) | Metalloproteinase inhibitoren | |
| JP3297053B2 (ja) | 金属タンパク質分解酵素阻害剤 | |
| EA023500B1 (ru) | Соединения, композиции и способы их применения для коррекции уровня мочевой кислоты | |
| BR9810841A (pt) | Inibidores de metaloprotease alicìclicos | |
| JPH11503746A (ja) | サクシンアミド誘導体と金属タンパク質分解酵素阻害剤としてのその使用 | |
| US20080188565A1 (en) | Hydroxamic acid derivatives of phenoxy-acetic acids and analogs useful as therapeutic agents for treating anthrax poisoning | |
| EA202091773A1 (ru) | Способ модуляции сигнальных путей tigit и pd-1 с применением 1,2,4-оксадиазольных соединений | |
| CR20240183A (es) | Inhibidores y/o degradadores de bckdk | |
| HUP9904664A2 (hu) | Mátrix metalloproteáz inhibitor hatású, helyettesített 4-bifenil-4-hidroxivajsav-származékok | |
| US20170267632A1 (en) | Methionine analogs and methods of using same | |
| KR19980703485A (ko) | 에폭시숙신산 유도체 | |
| JP2003519100A (ja) | ベータ二置換メタロプロテアーゼ阻害剤 | |
| MA53683A1 (fr) | Acide pyridyloxycarboxylique de type r, sel et dérivé ester de celui-ci, procédé de préparation correspondant, composition herbicide et utilisation associées | |
| JP3250806B2 (ja) | N−(メルカプトアシル)アミノ酸と、その製造方法と、その治療での使用と、それを含む医薬組成物 | |
| US20020068722A1 (en) | Alpha-substituted thio,-oxo trifluoromethylketones as phospholipase inhibitors | |
| RU2246941C2 (ru) | Антибактериальные агенты | |
| AU2002300119B2 (en) | Antibacterial agents | |
| JP2849810B2 (ja) | ヒト免疫不全ウイルス(hiv)プロテアーゼ阻害化合物、その製造方法、及びそれを含む組成物 | |
| DK163300B (da) | Analogifremgangsmaade til fremstilling af fluorerede alkandiaminderivater eller pharmaceutisk acceptable salte deraf | |
| JP2016006043A (ja) | 新規キノン誘導体およびそれを有効成分とする抗トリパノソーマ剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240703 Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20240703 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR PRIORITY RECEIVED Effective date: 20240703 Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240703 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W005 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: FIRST IPC ASSIGNED Effective date: 20240703 Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: IPC ASSIGNED Effective date: 20240703 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20240703 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241202 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241202 |